doi:10.3969/j.issn.1004-583X.2026.04.014

Abstract

CLC Number:

R692.5

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.04.014

https://www.lchc.cn/EN/Y2026/V41/I4/374

Figures/Tables 2

References 45

[1]	Kim HI, Park S. Sepsis: Early recognition and optimized treatment[J]. Tuberc Respir Dis (Seoul), 2019, 82(1):6-14. doi: 10.4046/trd.2018.0041.
[2]	Hird C. Early diagnosis and effective management of sepsis[J]. Nurs Stand, 2020, 35(10):59-66. doi: 10.7748/ns.2020.e11507.
[3]	Salomão R, Ferreira BL, Salomão MC, et al. Sepsis: Evolving concepts and challenges[J]. Braz J Med Biol Res, 2019, 52(4):e8595. doi: 10.1590/1414-431X20198595.
[4]	Srisawat N, Kellum JA. The role of biomarkers in acute kidney injury[J]. Crit Care Clin, 2020, 36(1):125-140. doi: 10.1016/j.ccc.2019.08.010. pmid: 31733675
[5]	Ganda IJ, Kasri Y, Susanti M, et al. Kidney injury molecule type-1, interleukin-18, and insulin-like growth factor binding protein 7 levels in urine to predict acute kidney injury in pediatric sepsis[J]. Front Pediatr, 2022, 10:1024713. doi: 10.3389/fped.2022.1024713.
[6]	Su Y, Gong Z, Wu Y, et al. Diagnostic value of urine tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 for acute kidney injury: A meta-analysis[J]. PLoS One, 2017, 12(1):e0170214. doi: 10.1371/journal.pone.0170214.
[7]	Yang H, Chen Y, He J, et al. Advances in the diagnosis of early biomarkers for acute kidney injury: A literature review[J]. BMC Nephrol, 2025, 26(1):115.doi: 10.1186/s12882-025-04040-3. pmid: 40045274
[8]	Atreya MR, Cvijanovich NZ, Fitzgerald JC, et al. Prognostic and predictive value of endothelial dysfunction biomarkers in sepsis-associated acute kidney injury: Risk-stratified analysis from a prospective observational cohort of pediatric septic shock[J]. Crit Care, 2023, 27(1):260. doi: 10.1186/s13054-023-04554-y.
[9]	Pennemans V, Rigo JM, Faes C, et al. Establishment of reference values for novel urinary biomarkers for renal damage in the healthy population: Are age and gender an issue?[J]. Clin Chem Lab Med, 2013, 51(9):1795-1802.doi: 10.1515/cclm-2013-0157. pmid: 23648635
[10]	王翔, 张志敏, 李建国, 等. CRRT与IHD治疗对脓毒症合并急性肾损伤患者尿IGFBP-7、NGAL及TIMP-2水平影响的比较[J]. 临床肾脏病杂志, 2022, 22(2):94-99.
[11]	Zhang J, Tian J, Sun H, et al. How does continuous renal replacement therapy affect septic acute kidney injury?[J]. Blood Purif, 2018, 46(4):326-331. doi: 10.1159/000492026.
[12]	An N, Chen R, Bai Y, et al. Efficacy and prognosis of continuous renal replacement therapy at different times in the treatment of patients with sepsis-induced acute kidney injury[J]. Am J Transl Res, 2021, 13(6):7124-7131. pmid: 34306472
[13]	Wu S, Xu T, Wu C, et al. Continuous renal replacement therapy in sepsis-associated acute kidney injury: Effects on inflammatory mediators and coagulation function[J]. Asian J Surg, 2021, 44(10):1254-1259. doi: 10.1016/j.asjsur.2021.02.004.
[14]	Zou F, Tang X, Lei X, et al. Treatment efficacy of continuous renal replacement on symptoms, inflammatory mediators, and coagulation function in patients with sepsis-associated acute kidney injury[J]. Arch Esp Urol, 2022, 75(9):746-752. doi: 10.56434/j.arch.esp.urol.20227509.109.
[15]	Feng S, Cui Y, Zhou Y, et al. Continuous renal replacement therapy attenuates polymorphonuclear myeloid-derived suppressor cell expansion in pediatric severe sepsis[J]. Front Immunol, 2022, 13:990522. doi: 10.3389/fimmu.2022.990522.
[16]	Fang J, Wang M, Gong S, et al. Increased 28-day mortality due to fluid overload prior to continuous renal replacement in sepsis associated acute kidney injury[J]. Ther Apher Dial, 2022, 26(2):288-296. doi: 10.1111/1744-9987.13727.
[17]	Song H, Liao Y, Hu H, et al. Mean arterial pressure at the initiation of continuous renal replacement therapy as a prognostic indicator in patients with acute kidney injury[J]. Ren Fail, 2025, 47(1):2448582. doi: 10.1080/0886022X.2024.2448582.
[18]	Kim Y, Yun D, Kwon S, et al. Target value of mean arterial pressure in patients undergoing continuous renal replacement therapy due to acute kidney injury[J]. BMC Nephrol, 2021, 22(1):20. doi: 10.1186/s12882-020-02227-4. pmid: 33422032
[19]	Sheng S, Zhang YH, Ma HK, et al. Albumin levels predict mortality in sepsis patients with acute kidney injury undergoing continuous renal replacement therapy: A secondary analysis based on a retrospective cohort study[J]. BMC Nephrol, 2022, 23(1):52. doi: 10.1186/s12882-021-02629-y. pmid: 35109818
[20]	Han S, Kim MJ, Ko HJ, et al. Diagnostic and prognostic roles of c-reactive protein, procalcitonin, and presepsin in acute kidney injury patients initiating continuous renal replacement therapy[J]. Diagnostics (Basel), 2023, 13(4):777. doi: 10.3390/diagnostics13040777.
[21]	Lee J, Song J, Kim SG, et al. Mortality associated with the neutrophil-lymphocyte ratio in septic acute kidney injury requiring continuous renal replacement therapy[J]. Kidney Res Clin Pract, 2024, 43(3):337-347. doi: 10.23876/j.krcp.23.116. pmid: 38325867
[22]	Zhang J, Long M, Sun Z, et al. Association between thymosin beta-4, acute kidney injury, and mortality in patients with sepsis: An observational cohort study[J]. Int Immunopharmacol, 2021, 101(Pt A):108167. doi: 10.1016/j.intimp.2021.108167.
[23]	Cho AY, Yoon HJ, Lee KY, et al. Clinical characteristics of sepsis-induced acute kidney injury in patients undergoing continuous renal replacement therapy[J]. Ren Fail, 2018, 40(1):403-409. doi: 10.1080/0886022X.2018.1489288. pmid: 30015549
[24]	Kim IY, Ye BM, Kim SR, et al. Sarcopenia is independently associated with mortality and recovery from dialysis in critically ill patients with sepsis-induced acute kidney injury receiving continuous renal replacement therapy[J]. Kidney Res Clin Pract, 2025, 44(2):324-337. doi: 10.23876/j.krcp.24.015.
[25]	Cai C, Qiu G, Hong W, et al. Clinical effect and safety of continuous renal replacement therapy in the treatment of neonatal sepsis-related acute kidney injury[J]. BMC Nephrol, 2020, 21(1):286. doi: 10.1186/s12882-020-01945-z. pmid: 32682407
[26]	Karkar A, Ronco C. Prescription of CRRT: A pathway to optimize therapy[J]. Ann Intensive Care, 2020, 10(1):32. doi: 10.1186/s13613-020-0648-y. pmid: 32144519
[27]	Kestriani N, Pradian E, Alifahna M. Continuous renal replacement therapy versus intermittent hemodialysis in intensive care patients: Impact on mortality and length of stay[J] .ANAESTH PAIN INTENSI, 2024, 28(6):1061-1066.doi:10.35975/apic.v28i6.2623.
[28]	An MM, Liu CX, Gong P. Effects of continuous renal replacement therapy on inflammation-related anemia, iron metabolism and prognosis in sepsis patients with acute kidney injury[J]. World J Emerg Med, 2023, 14(3):186-192. doi: 10.5847/wjem.j.1920-8642.2023.052.
[29]	Okano H, Okamoto H, Tanaka H, et al. Comparison of intermittent and continuous renal replacement therapy for sepsis-associated AKI: A retrospective analysis of the Japanese ICU database[J]. JA Clin Rep, 2025, 11(1):24. doi: 10.1186/s40981-025-00787-8. pmid: 40293602
[30]	Li E, Zhang L, He Y, et al. Continuous renal replacement therapy versus intermittent hemodialysis for renal prognosis in elderly patients with acute kidney injury[J]. Int J Nephrol, 2025, 2025:8899604. doi: 10.1155/ijne/8899604.
[31]	Park CH, Koh HB, Lee JH, et al. Volume control strategy and patient survival in sepsis-associated acute kidney injury receiving continuous renal replacement therapy: A randomized controlled trial with secondary analysis[J]. Sci Rep, 2024, 14(1):14284. doi: 10.1038/s41598-024-64224-z. pmid: 38902283
[32]	Zhao CL, Zhao MY, Wang H, et al. Early net ultrafiltration thresholds and mortality in critically ill patients with septic acute kidney injury receiving continuous renal replacement therapy[J]. Ren Fail, 2025, 47(1):2511277. doi: 10.1080/0886022X.2025.2511277.
[33]	许涛, 盛晓华, 崔勇平, 等. CRRT在脓毒血症急性肾损伤患者救治中的临床研究[J]. 中国血液净化, 2013, 12(12):646-650.
[34]	Chen WY, Cai LH, Zhang ZH, et al. The timing of continuous renal replacement therapy initiation in sepsis-associated acute kidney injury in the intensive care unit: The CRTSAKI Study (Continuous RRT Timing in Sepsis-associated AKI in ICU): Study protocol for a multicentre, randomised controlled trial[J]. BMJ Open, 2021, 11(2):e040718. doi: 10.1136/bmjopen-2020-040718.
[35]	Gaudry S, Hajage D, Benichou N, et al. Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: A systematic review and individual patient data meta-analysis of randomised clinical trials[J]. Lancet, 2020, 395(10235):1506-1515. doi: 10.1016/S0140-6736(20)30531-6. pmid: 32334654
[36]	Zhuang C, Hu R, Li K, et al. Machine learning prediction models for mortality risk in sepsis-associated acute kidney injury: Evaluating early versus late CRRT initiation[J]. Front Med (Lausanne), 2025, 11:1483710. doi: 10.3389/fmed.2024.1483710.
[37]	Guan M, Wang H, Tang X, et al. Continuous renal replacement therapy with adsorbing filter oXiris in acute kidney injury with septic shock: A retrospective observational study[J]. Front Med (Lausanne), 2022, 9:789623. doi: 10.3389/fmed.2022.789623.
[38]	Liu S, Cao Q, Sun R, et al. Application of different continuous renal replacement therapy hemofilter in patients with septic shock complicated with acute renal injury[J]. Iran J Public Health, 2022, 51(10):2317-2324. doi: 10.18502/ijph.v51i10.10990. pmid: 36415800
[39]	He SQ, Lou J, Li YS, et al. Efficacy and prognostic analysis of the oXiris^® filter in sepsis-associated acute kidney injury[J]. Int Urol Nephrol, 2025, 57(10):3387-3397. doi: 10.1007/s11255-025-04533-y.
[40]	Mariano F, Greco' D, Depetris N, et al. CytoSorb^® in burn patients with septic shock and acute kidney injury on continuous kidney replacement therapy is associated with improved clinical outcome and survival[J]. Burns, 2024, 50(5):1213-1222. doi: 10.1016/j.burns.2024.02.028.
[41]	Liu D, Zhao J, Xia H, et al. Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: A retrospective single-center study[J]. Eur J Med Res, 2024, 29(1):72. doi: 10.1186/s40001-024-01660-7. pmid: 38245802
[42]	Miao M, Chen Z. Impact of nafamostat mesylate combined with continuous renal replacement therapy on clinical outcomes, immune function, and oxidative stress markers in patients with sepsis-associated acute kidney injury[J]. Br J Hosp Med (Lond), 2025, 86(2):1-13. doi: 10.12968/hmed.2024.0615. pmid: 39998131
[43]	Ouyang L, Pan Y, Wu YF, et al. Early and high-volume administration of sodium bicarbonate in sepsis-associated acute kidney injury in patients with malignancies, during continuous renal replacement therapy[J]. Ren Fail, 2025, 47(1):2443026. doi: 10.1080/0886022X.2024.2443026.
[44]	Bjørklund G, Peana M, Maes M, et al. The glutathione system in Parkinson's disease and its progression[J]. Neurosci Biobehav Rev, 2021, 120:470-478. doi: 10.1016/j.neubiorev.2020.10.004. pmid: 33068556
[45]	Liu H, Tian Y, Liu C, et al. Effect of glutathione-assisted continuous renal replacement therapy in sepsis patients with acute renal injury[J]. Clin Nephrol, 2024, 101(4):191-198. doi: 10.5414/CN111220. pmid: 38329917

生物标记物	诊断AKI价值	优势场景
IGFBP-7	敏感度高,升高时间窗极早	识别早期亚临床肾损伤
TIMP-2	联合IGFBP-7,提高AKI诊断准确性	AKI早期预警
NGAL	与AKI严重程度正相关	AKI早期预警
KIM-1	对肾小管损伤特异性高	鉴别缺血性/中毒性肾小管损伤
PENK	与AKI严重程度正相关	预后预测价值
IL-18	对肾小管损伤特异性高	提高脓毒症AKI诊断准确性
神经轴突导向因子-1	对肾小管损伤特异性高	预后预测价值

生物标记物	诊断AKI价值	优势场景
IGFBP-7	敏感度高,升高时间窗极早	识别早期亚临床肾损伤
TIMP-2	联合IGFBP-7,提高AKI诊断准确性	AKI早期预警
NGAL	与AKI严重程度正相关	AKI早期预警
KIM-1	对肾小管损伤特异性高	鉴别缺血性/中毒性肾小管损伤
PENK	与AKI严重程度正相关	预后预测价值
IL-18	对肾小管损伤特异性高	提高脓毒症AKI诊断准确性
神经轴突导向因子-1	对肾小管损伤特异性高	预后预测价值

指标	CRRT	IHD	优势倾向
血流动力学稳定性	血流动力学平稳,耐受性好	快速超滤,易发生低血压	CRRT
对脏器功能保护	利于保护心、脑、肾等脏器	脏器保护作用较弱	CRRT
医护与资源需求	人力、耗材及费用较高	操作简便,资源消耗较低	IHD
并发症发生率	相对安全,不良事件发生率低	不良心血管事件发生率较高	CRRT
脓毒症合并AKI病死率	预后好,病死率低	安全性差,病死率高	CRRT

指标	CRRT	IHD	优势倾向
血流动力学稳定性	血流动力学平稳,耐受性好	快速超滤,易发生低血压	CRRT
对脏器功能保护	利于保护心、脑、肾等脏器	脏器保护作用较弱	CRRT
医护与资源需求	人力、耗材及费用较高	操作简便,资源消耗较低	IHD
并发症发生率	相对安全,不良事件发生率低	不良心血管事件发生率较高	CRRT
脓毒症合并AKI病死率	预后好,病死率低	安全性差,病死率高	CRRT

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 45

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Jiang Shaoli, Yan Guosheng, Li Lili. Incidence and risk factors of malnutrition-inflammation complex syndrome in patients receiving maintenance hemodialysis at the end stage of renal disease [J]. Clinical Focus, 2026, 41(4): 312-317.
[2]	Wang Yan, Yang Heng. Mediating effect of disease uncertainty on the relationship between health literacy and anxiety in uremic dialysis patients [J]. Clinical Focus, 2026, 41(4): 318-322.
[3]	. [J]. Clinical Focus, 2026, 41(1): 84-90.
[4]	Zhang Hui, Zhang Wenbo, Liang Wenqi, Huo Yanhong. Idiopathic renal hypouricemia combined with repeated acute kidney injury: A case report and literature review [J]. Clinical Focus, 2025, 40(2): 168-171.
[5]	Pu Qian, Cheng Gang, Dao Jiecao, Qi Zizhao, Dou Lele, Zhao Junfang, Zhang Wenjun, Guo Caixia, Wang Yingying. Risk factors for constipation in patients with chronic kidney disease in Gansu province: a single-center study [J]. Clinical Focus, 2025, 40(1): 44-53.
[6]	Liu Yi, Zhao Haotian, Wang Xiaona, Liu Yuanlin, Li Li, Wang Zekai. Application value of right heart ultrasound combined with renal vascular doppler score in patients with end-stage renal disease during dialysis [J]. Clinical Focus, 2025, 40(1): 54-59.
[7]	Guo Xiaocui, Yu Xiaojuan, Shen Xia, Ye Shuiying, Zhou Dongchi, Lai Bihong. Effect of a multidisciplinary intervention on the quality of life in maintenance hemodialysis patients [J]. Clinical Focus, 2024, 39(9): 803-807.
[8]	. [J]. Clinical Focus, 2024, 39(9): 847-850.
[9]	. [J]. Clinical Focus, 2024, 39(2): 183-187.
[10]	Wang Lingling, Wu Jinlan, Wu Wei, Shen Shipeng, Chi Yanqing, Liu Maodong. A meta-analysis of the renal protective effects of vitamin D and its analogues in non dialysis patients with chronic kidney disease [J]. Clinical Focus, 2022, 37(12): 1081-1088.
[11]	Wang Pengrui, Chen Huaqian, Yang Tao, Zhao Li, Li Peng. The effect of serum intact parathyroid hormone level on the maturation of autogeneous arteriovenous fistula [J]. Clinical Focus, 2022, 37(12): 1094-1098.
[12]	Li Yingying, Li Ting, Zhang Ming, Fan Minghua, Xing Guangqun. Monitoring significance of CD4⁺ T lymphocyte count on evaluating frailty status of chronic renal failure in patients [J]. Clinical Focus, 2022, 37(3): 243-247.
[13]	Li Wenzhe, Shang Jinchun, Li Chunmei, Tian Fen, Li Jun, Cui Li, Xing Guangqun. Risk factors of cerebral hemorrhage in uremic patients on regular hemodialysis [J]. Clinical Focus, 2022, 37(1): 20-25.
[14]	Li Wenzhe, Shang Jinchun, Li Chunmei, Li Jun, Tian Fen, Cui Li, Chen Yipeng, Zhang Xiaofan, Xing Guangqun. Effect of sodium citrate anticoagulation in continuous renal replacement therapy on uremic patients with cerebral hemorrhage [J]. Clinical Focus, 2021, 36(5): 425-431.
[15]	Zhang Linli, Ma Xiaohong. Clinical features and risk factors of acute kidney injury after hip fracture in the elderly [J]. Clinical Focus, 2021, 36(5): 442-445.